Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 101–200 of 1,001
Epigenetic mechanisms of importance for drug treatment
Ivanov, M., Barragan, I., & Ingelman-Sundberg, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.004 · Cited by 159
Insights into newly discovered marks and readers of epigenetic information
Andrews, F. H., Strahl, B. D., & Kutateladze, T. G. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2149 · Cited by 175
Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
The methyltransferase G9a regulates HoxA9-dependent transcription in AML
Lehnertz, B., Pabst, C., Su, L., Miller, M., Liu, F., Yi, L., Zhang, R., Krosl, J., Yung, E., Kirschner, J., et al. (2014) · Genes & Development · doi:10.1101/gad.236794.113 · Cited by 152
“2009) in the pathology of human leukemias has stimulated a great deal of interest in identifying chromatin-modifying enzymes that can be targeted therapeutically (Arrowsmith et al. 2012; Dawson and Kouzarides 2012).”
BackgroundCancer epigenetics drug discovery and development: the challenge of hitting the mark
Campbell, R. M., & Tummino, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71605 · Cited by 149
“…and histone acetyltranferases) and “erase” the histone code (histone demethylases and histone deacetylases), there are epigenetic proteins that “read” the epigenetic code by binding to methylated or acetylated histone residues as part of mechanisms of transcriptional regulation (49).”
Meeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 162
Understanding histone H3 lysine 36 methylation and its deregulation in disease
Li, J., Ahn, J. H., & Wang, G. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03144-y · Cited by 159
Fundamentals of vitamin D hormone-regulated gene expression
Pike, J. W., & Meyer, M. B. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.11.004 · Cited by 141
Next-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 155
Chemical genomics reveals histone deacetylases are required for core regulatory transcription
Gryder, B. E., Wu, L., Woldemichael, G. M., Pomella, S., Quinn, T. R., Park, P. M. C., Cleveland, A., Stanton, B. Z., Song, Y., Rota, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11046-7 · Cited by 144
Epigenetics of idiopathic pulmonary fibrosis
Yang, I. V., & Schwartz, D. A. (2015) · Translational Research · doi:10.1016/j.trsl.2014.03.011 · Cited by 139
“Moreover, current FDA-approved and in development histone mark modifying drugs are effective in targeting specific pathways [66] and treating diseases such as lung cancer [142].”
BackgroundOptimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
Hewings, D. S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C., Olcina, M. M., Freeman, K., Gill, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301588r · Cited by 137
Fiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S. G. T., Leveque, C., Portier, B. P., Iyer, S., Bradner, J. E., & Bhalla, K. N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0258 · Cited by 137
“The family of bromodomain and extraterminal (BET) proteins, includingBRD4, are chromatin "reader" proteins that contain the N-terminal double, tandem, 110 amino acids long bromodomains, throughwhich they bind to the acetylated lysines on histone proteins (18, 19).”
Park‐Min, K., Lim, E., Lee, M. J., Park, S. H., Γιαννοπούλου, Ε., Yarilina, A., van der Meulen, M. C. H., Zhao, B., Smithers, N. N., Witherington, J. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6418 · Cited by 146
Self-citationZhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
Valente, S., Liu, Y., Schnekenburger, M., Zwergel, C., Cosconati, S., Gros, C., Tardugno, M., Labella, D., Florean, C., Minden, S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4012627 · Cited by 145
Transgenerational Epigenetic Effects on Brain Functions
Bohacek, J., Gapp, K., Saab, B. J., & Mansuy, I. M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.019 · Cited by 152
Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches
da Silva, S. D., Hier, M., Mlynarek, A., Kowalski, L. P., & Alaoui‐Jamali, M. A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00149 · Cited by 148
“Therefore several emerging approaches targeting key signaling molecules critical to CSC, and cancer epigenetics and metabolism are under extensive investigation (Grskovic et al., 2011; Vander Heiden, 2011; Arrowsmith et al., 2012).”
BackgroundSelective Inhibitors of Protein Methyltransferases
Kanıskan, H. Ü., Konze, K. D., & Jin, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501234a · Cited by 143
Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
Kagohara, L. T., Stein-O’Brien, G., Kelley, D. Z., Flam, E. L., Wick, H. C., Danilova, L., Easwaran, H., Favorov, A. V., Qian, J. X., Gaykalova, D. A., et al. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx018 · Cited by 149
Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy
Wang, J., Yu, J., Tan, M., Jiang, T., & Tan, L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.05.003 · Cited by 153
Advances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 142
“Proteins that recognize histone and DNA modifications are the chromatin “readers” [1].”
BackgroundLLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
Nguyen, H., Allali‐Hassani, A., Antonysamy, S., Chang, S. S., Chen, L. H., Curtis, C., Emtage, S., Li, F., Gheyi, T., Li, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626861 · Cited by 137
Self-citationHorton, J. R., Engstrom, A., Zoeller, E. L., Liu, X., Shanks, J. R., Zhang, X., Johns, M. A., Vertino, P. M., Fu, H., & Cheng, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698449 · Cited by 145
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling
Scheer, S., Ackloo, S. Z., Medina, T. D. S., Schapira, M., Li, F., Ward, J. A., Lewis, A. M., Northrop, J. P., Richardson, P. L., Kanıskan, H. Ü., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07905-4 · Cited by 138
Self-citationBots, M., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K., Shortt, J., Ossenkoppele, G. J., Zuber, J., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 133
Klaus, C. R., Iwanowicz, D., Johnston, D., Campbell, C. T., Smith, J. J., Moyer, M. P., Copeland, R. A., Olhava, E. J., Scott, M. P., Pollock, R. M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214577 · Cited by 137
“20 methylation of chromosomal DNA at CpG islands by the DNA methyltransferases (DNMTs) (Arrowsmith et al., 2012; Kouzarides, 2007).”
BackgroundHistone acetyltransferase inhibitors block neuroblastoma cell growth in vivo
Gajer, J. M., Furdas, S. D., Gründer, A., Gothwal, M., Heinicke, U., Keller, K., Colland, F., Fulda, S., Pahl, H. L., Fichtner, I., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2014.51 · Cited by 127
Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer
Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., & Johnsen, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1875 · Cited by 140
“If the signal is not stopped in a timely manner, the results can lead to defects in transcription and DNA repair ultimately promoting tumorigenesis of tumor progression [96].”
BackgroundDzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 127
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Bass, A. K. A., El‐Zoghbi, M. S., Nageeb, E.-S. M., Mohamed, M. F. A., Badr, M., & Abuo‐Rahma, G. E. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112904 · Cited by 132
Mutations in SETD2 cause a novel overgrowth condition
Luscan, A., Laurendeau, I., Malan, V., Francannet, C., Odent, S., Giuliano, F., Lacombe, D., Touraine, R., Vidaud, M., Pasmant, E., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102402 · Cited by 131
Jurdzinski, K. T., Potempa, J., & Grabiec, A. M. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00982-7 · Cited by 146
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Wu, Q., Nie, D. Y., Ba-Alawi, W., Ji, Y., Zhang, Z., Cruickshank, J., Haight, J., Ciamponi, F. E., Chen, J., Duan, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01024-4 · Cited by 141
Self-citationMarek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122
Targeting EZH2 and PRC2 dependence as novel anticancer therapy
Xu, B., Konze, K. D., Jin, J., & Wang, G. G. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.001 · Cited by 124
“Deregulation of these chromatin regulatory mechanisms is directly involved in oncogenesis, including hematopoietic malignancies [3, 4, 6-9].”
BackgroundEpigenetic Regulation of Monocyte and Macrophage Function
Hoeksema, M. A., & de Winther, M. P. J. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6695 · Cited by 121
“Hdac inhibitors are the most extensively studied epigenetic pharmaceuticals and are currently thoroughly tested in clinical trials for the treatment of various cancers (3).”
BackgroundThe application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 133
Wang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
“, 2010), the sulfhydryl group of romidepsin is thought to chelate zinc with little specificity (Arrowsmith et al., 2012).”
DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies
Pechalrieu, D., Etiévant, C., & Arimondo, P. B. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.004 · Cited by 127
Law, R. P., Atkinson, S. J., Bamborough, P., Chung, C.-W., Demont, E. H., Gordon, L. J., Lindon, M., Prinjha, R. K., Watson, A. J. B., & Hirst, D. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01666 · Cited by 117
The Epigenetic Regulation of HCC Metastasis
Han, T., Ban, H. S., Hur, K., & Cho, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123978 · Cited by 128
BET bromodomain inhibitors: a patent review
Garnier, J.-M., Sharp, P. P., & Burns, C. J. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859244 · Cited by 119
“The clinical utility of, and experience with, HDAC inhibitors and DNAmethyl transferase inhibitors in the treatment of specific cancers has given impetus to the discovery of new drugs selectively targeting other epigenetic processes for cancer and other diseases [101].”
BackgroundZhao, L., Cao, D., Chen, T., Wang, Y., Miao, Z., Xu, Y., Chen, W., Wang, X., Li, Y., Du, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301793a · Cited by 119
Gene-by-environment interactions in urban populations modulate risk phenotypes
Favé, M.-J., Lamaze, F. C., Soave, D., Hodgkinson, A., Gauvin, H., Bruat, V., Grenier, J.-C., Gbeha, E., Skead, K., Smargiassi, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03202-2 · Cited by 117
Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 123
Cortés-Ciriano, I., Ain, Q. U., Subramanian, V., Lenselink, E. B., Méndez-Lucio, O., IJzerman, A. P., Wohlfahrt, G., Prusis, P., Malliavin, T. E., van Westen, G. J. P., et al. (2015) · MedChemComm · doi:10.1039/c4md00216d · Cited by 116
Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
Ma, A., Yu, W., Li, F., Bleich, R. M., Herold, J. M., Butler, K. V., Norris, J. L., Korboukh, V. K., Tripathy, A., Janzen, W. P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500871s · Cited by 123
Self-citationEpigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease
Adwan, L., & Zawia, N. H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.010 · Cited by 115
“EVP-0334 is an HDAC inhibitor developed for AD by EnVivo Pharmaceuticals that successfully completedphase I clinical trials andwas deemed safe for further testing, however, detailed information on the trial have not been made available yet (Mack, 2010; Arrowsmith et al., 2012; Caraci et al., 2012).”
Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease
Sincennes, M., Brun, C. E., & Rudnicki, M. A. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0266 · Cited by 132
Epigenetic drugs in cancer therapy
Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10253-7 · Cited by 140
Bromodomain Histone Readers and Cancer
Jain, A. K., & Barton, M. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.020 · Cited by 123
Oncogenic human papillomaviruses
McBride, A. A. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0273 · Cited by 112
4‐Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
Lucas, X., Wohlwend, D., Hügle, M. J., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., & Günther, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307652 · Cited by 120
The role of histone demethylases in cancer therapy
Hoffmann, I., Roatsch, M., Schmitt, M., Carlino, L., Pippel, M., Sippl, W., & Jung, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.004 · Cited by 121
“This also allows for removal of a trimethyl mark, which is not possible for LSD1-type demethylases for chemical reasons (Arrowsmith et al., 2012; Tsukada et al., 2006; Whetstine et al., 2006).”
BackgroundVeschi, V., Liu, Z., Voss, T. C., Ozbun, L. L., Gryder, B. E., Yan, C., Hu, Y., Ma, A., Jin, J. J., Mazur, S. J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.002 · Cited by 113
“Alterations in epigenetic machinery, including mutations or overexpression of chromatin remodelers and modifiers, as well as DNA hypermethylation, can disrupt normal development, resulting in pathologies, including cancer (Arrowsmith et al., 2012; Jones and Baylin, 2007).”
Self-citationAssay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Dahlin, J. L., Nelson, K. M., Strasser, J. M., Baršytė-Lovejoy, D., Szewczyk, M. M., Organ, S. L., Cuellar, M. E., Singh, G., Shrimp, J. H., Nguyen, N. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01657-3 · Cited by 113
Self-citationFragment-based discovery of a chemical probe for the PWWP1 domain of NSD3
Böttcher, J., Dilworth, D., Reiser, U., Neumüller, R. A., Schleicher, M., Petronczki, M. P., Zeeb, M., Mischerikow, N., Allali‐Hassani, A., Szewczyk, M. M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0310-x · Cited by 109
Self-citationTargeting EZH2 for cancer therapy: From current progress to novel strategies
Zeng, J., Zhang, J., Sun, Y. J., Wang, J., Ren, C., Banerjee, S., Ouyang, L., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114419 · Cited by 114
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M.-M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 106
Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking
Li, X., Li, X.-M., Jiang, Y., Liu, Z., Cui, Y., Fung, K. Y., van der Beelen, S. H. E., Tian, G., Wan, L., Shi, X., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0144-y · Cited by 110
Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia
Gu, Z., Liu, Y., Zhang, Y., Cao, H., Lyu, J., Wang, X., Wylie, A., Newkirk, S. J., Jones, A. E., Lee, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00829-8 · Cited by 115
Epigenetic regulation in neurodevelopment and neurodegenerative diseases
Gapp, K., Woldemichael, B. T., Bohacek, J., & Mansuy, I. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.040 · Cited by 104
“Ultimately, a better profiling of epigenetic alterations in patients may provide new options for potential diagnostic use and for the development of epigenetic drug treatment (Arrowsmith et al., 2012).”
BackgroundEpigenetic control of HIV-1 post integration latency: implications for therapy
Kumar, A., Darcis, G., Lint, C. M. V., & Herbein, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0137-6 · Cited by 115
“HATs add acetyl group to the ε-amino group of lysine residues in histone tails which generally result in active gene expression and compete with HDACs that blunt transcription by reducing accessibility of DNA templates [53, 54].”
BackgroundTargeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer
Raynal, N. J. ‐., Lee, J. T., Wang, Y., Beaudry, A., Madireddi, P., Garriga, J., Malouf, G. G., Dumont, S., Dettman, E. J., Gharibyan, V., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-2391 · Cited by 110
“effects outside of a restricted patient population (5).”
Olsen, J. B., Cao, X.-J., Han, B., Chen, L. H., Horvath, A., Richardson, T. I., Campbell, R. M., Garcia, B. A., & Nguyen, H. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053280 · Cited by 111
Beyond histones – the expanding roles of protein lysine methylation
Wu, Z., Connolly, J., & Biggar, K. K. (2017) · FEBS Journal · doi:10.1111/febs.14056 · Cited by 116
Diversity of the reaction mechanisms of SAM-dependent enzymes
Sun, Q., Huang, M., & Wei, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.011 · Cited by 112
Chua, M. J., Arnold, M. S. J., Xu, W., Lancelot, J., Lamotte, S., Späth, G. F., Prina, E., Pierce, R. J., Fairlie, D. P., Skinner‐Adams, T. S., et al. (2016) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2016.12.005 · Cited by 108
“Histone/ lysine deacetylases and acetyltransferases, respectively, remove and add acetyl groups from histones and other proteins, just as corresponding demethylases and methyltransferases remove and add methyl groups to lysine sidechains of proteins (Arrowsmith et al., 2012).”
BackgroundThe Genetic Basis of Peyronie Disease: A Review
Herati, A. S., & Pastuszak, A. W. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2015.10.002 · Cited by 104
Rotili, D., Tarantino, D., Nebbioso, A., Paolini, C., Huidobro, C., Lara, E., Mellini, P., Lenoci, A., Pezzi, R., Botta, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011614 · Cited by 108
Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation
Antignano, F., Burrows, K., Hughes, M. R., Han, J. M., Kron, K. J., Penrod, N. M., Oudhoff, M. J., Wang, S. K. H., Min, P. H., Gold, M. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69592 · Cited by 107
“Our results suggest that modulation of G9Adependent H3K9me2 may be used to manipulate the balance of Th cell subsets and that “epigenetic therapy” (65) may prove useful in the treatment of IBD and other autoimmune or autoinflammatory diseases associated with dysregulated Th17 and Treg responses.”
Self-citationYakovlev, I., Carneros, E., Lee, Y., Olsen, J. E., & Fossdal, C. G. (2016) · Planta · doi:10.1007/s00425-016-2484-8 · Cited by 109
“…of the literature describing specific genes and multiple active domains typical for epigenetic regulators in a large number of organisms [e.g., (Arrowsmith et al. 2012; Musselman et al. 2012; Lu 2013; Pikaard and Mittelsten Scheid 2014); additional references in the relevant paragraphs in…”
BackgroundHost–microbiota interactions: epigenomic regulation
Woo, V., & Alenghat, T. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.12.001 · Cited by 99
“Changes in chromatin state through condensation and relaxation allow for DNA replication and repair [12,13].”
BackgroundPappano, W. N., Guo, J., He, Y., Ferguson, D., Jagadeeswaran, S., Osterling, D. J., Gao, W., Spence, J. K., Pliushchev, M., Sweis, R. F., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131716 · Cited by 96
“HMTs have recently generated increased interest as potential targets of therapeutic value in human disease, especially since these epigenetic modifications are reversible [5, 6].”
BackgroundKMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells
Metzger, E., Wang, S., Urban, S., Willmann, D., Schmidt, A., Offermann, A., Allen, A., Sum, M., Obier, N., Cottard, F., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0219-9 · Cited by 100
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts
Bae, S., Kim, K., Kang, K., Kim, H., Lee, M. J., Oh, B., Kaneko, K., Ma, S., Choi, J., Kwak, H., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00959-x · Cited by 108
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 107
“It has been hypothesized that class IIa HDACs serve as recruiters or “readers” to specific promoter regions, where HDAC3 would act as the deacetylase [13, 14].”
BackgroundEpigenetics, chromatin and genome organization: recent advances from the ENCODE project
Siggens, L., & Ekwall, K. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12231 · Cited by 98
The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
Loo Yau, H., Ettayebi, I., & De Carvalho, D. D. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.006 · Cited by 96
NF-κB: Regulation by Methylation
Lu, T., & Stark, G. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1022 · Cited by 101
“As shown in Supplementary Table 1 regarding the methylation of NF-κB, we can find examples of both Writer and Erasers, but not Readers.”
InfluentialMYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
Lodrini, M., Oehme, I., Schroeder, C., Milde, T., Schier, M. C., Kopp-Schneider, A., Schulte, J. H., Fischer, M., De Preter, K., Pattyn, F., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt346 · Cited by 96
“We next tested the influence of the clinically more advanced pan-HDAC inhibitors, Panobinostat, PCI-24781 and Vorinostat (31), on miR-183 expression in these four cell lines after 24 h of continuous treatment.”
MethodInfluentialSchistosoma mansoni Sirtuins: Characterization and Potential as Chemotherapeutic Targets
Lancelot, J., Caby, S., Dubois-Abdesselem, F., Vanderstraete, M., Trolet, J., Oliveira, G., Bracher, F., Jung, M., & Pierce, R. J. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002428 · Cited by 95
“One compound (Selisistat or SEN196) is in Phase II clinical trials for Huntington’s disease [7].”
BackgroundChromoHub: a data hub for navigators of chromatin-mediated signalling
Liu, L., Zhen, X. T., Denton, E., Marsden, B. D., & Schapira, M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts340 · Cited by 93
“Chromatin-mediated control of gene expression and cell fate is regulated in part by distinct combinations of post-translational modifications on histone proteins, predominantly methylation or acetylation of lysine or arginine side chains at the N-terminal tails of histones (Fierz and Muir, 2012;…”
BackgroundSelf-citationProspects for the development of epigenetic drugs for CNS conditions
Szyf, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4580 · Cited by 105
Role of Histone-Modifying Enzymes and Their Complexes in Regulation of Chromatin Biology
DesJarlais, R. L., & Tummino, P. J. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01210 · Cited by 110
Duan, Y., Ma, Y., Qin, W., Ding, L., Zheng, Y., Zhu, Y., Zhai, X.-Y., Yang, J. C., Ma, C.-Y., & Guan, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.038 · Cited by 96
“Epigenetic regulators like lysine specific demethylase1(LSD1) and histone deacetylase s (HDACs) are being increasingly used as targets for chemotherapeutic i ntervention in cancers [5].”
BackgroundPreserving genome integrity and function: the DNA damage response and histone modifications
Kim, J. J., Lee, S. Y., & Miller, K. M. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1620676 · Cited by 104
“Histone PTMs can also function as high-affinity binding sites for proteins that contain “reader” domains that recognize specific histone marks (Figure 1) (Arrowsmith et al. 2012; Musselman et al. 2012).”
BackgroundLight-controlled modulation of gene expression by chemical optoepigenetic probes
Reis, S. A., Ghosh, B., Hendricks, J. A., Szantai‐Kis, D. M., Toerk, L., Ross, K. N., Lamb, J., Read-Button, W., Zheng, B., Wang, H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2042 · Cited by 106
“” Nature chemical biology 12 (5): 317-323.”
Unravelling the genomic targets of small molecules using high-throughput sequencing
Rodriguez, R., & Miller, K. M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3796 · Cited by 111
Discovery of a PCAF Bromodomain Chemical Probe
Moustakim, M., Clark, P. G. K., Trulli, L., de Arriba, A. L. F., Ehebauer, M. T., Chaikuad, A., Murphy, E. J., Méndez, J., Daniels, D. L., Hou, C.-F. D., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201610816 · Cited by 94
Woo, V., Eshleman, E. M., Hashimoto‐Hill, S., Whitt, J., Wu, S.-E., Engleman, L., Rice, T., Karns, R. A., Qualls, J. E., Haslam, D. B., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.09.010 · Cited by 98
Transcriptome of interstitial cells of Cajal reveals unique and selective gene signatures
Lee, M. Y., Ha, S. E., Park, C., Park, P. J., Fuchs, R., Wei, L., Jorgensen, B. G., Redelman, D., Ward, S. M., Sanders, K. M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176031 · Cited by 94
Structure-guided discovery of the metabolite carboxy-SAM that modulates tRNA function
Kim, J., Xiao, H., Bonanno, J. B., Kalyanaraman, C., Brown, S. D., Tang, X., Al-Obaidi, N. F., Patskovsky, Y., Babbitt, P. C., Jacobson, M. P., et al. (2013) · Nature · doi:10.1038/nature12180 · Cited by 93
Gamal-Eldin, M. A., & Macartney, D. H. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob27007b · Cited by 93
Suzuki, T., Ozasa, H., Itoh, Y., Zhan, P., Sawada, H., Mino, K., Walport, L. J., Ohkubo, R., Kawamura, A., Yonezawa, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400624b · Cited by 93
Cribbs, A. P., Hookway, E. S., Wells, G., Lindow, M., Obad, S., Oerum, H., Prinjha, R. K., Athanasou, N. A., Sowman, A., Philpott, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000698 · Cited by 97
“The dynamic nature of chromatin modification has now been realized, and recognition of specific modifications by several proteins has enabled the concept of a chromatin or “histone code” (18).”
BackgroundEpigenetics of myelodysplastic syndromes
Itzykson, R., & Fenaux, P. (2013) · Leukemia · doi:10.1038/leu.2013.343 · Cited by 100
Genome-wide epigenomic profiling for biomarker discovery
Dirks, R. A. M., Stunnenberg, H. G., & Marks, H. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0284-4 · Cited by 100
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.